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Introduction: We investigated how many patients, who presented with Raynaud’s phenomenon (RP) and who had
not been classified as systemic sclerosis (SSc), would be reclassified as SSc, if the 2013 American College of
Rheumatology (ACR)/the European League Against Rheumatism (EULAR) classification criteria were used. We also
analyzed the predictive values of the reclassification as SSc in those patients.
Methods: We consecutively enrolled 64 patients with RP and 60 patients with SSc. We applied the new
classification criteria to them, reclassified them, and compared variables between those who were newly classified
as SSc and those who were not or previously classified as SSc.
Results: Seventeen of 64 patients (26.5%), who presented with RP, but did not fulfill the 1980 ACR classification
criteria, were newly classified as SSc by the 2013 ACR/EULAR classification criteria. The newly classified patients as
SSc showed increased frequencies of sclerodactyly, digital tip ulcer, telangiectasia, abnormal nailfold capillaries and
the presence of anti-centromere antibody, compared to those not and telangiectasia and anti-centromere antibody,
compared to the previously classified patients. For the reclassification as SSc, the variables with independent
predictive value were sclerodactyly (odds ratio (OR) 60.025), telangiectasia (OR 13.353) and the presence of
anti-centromere antibody (OR 11.168).
Conclusions: Overall, 26.5% of the patients, who presented with RP, but who did not fulfill the 1980 ACR
classification criteria, were newly classified as SSc according to the 2013 ACR/EULAR classification criteria.
Sclerodactyly, telangiectasia, and the presence of anti-centromere antibody had independent predictive value for
reclassifying patients with RP as SSc.Introduction
Raynaud’s phenomenon (RP) is a reversible vasculopathy
characterized by pallor and cyanosis due to cold-induced
paroxysmal spasms of the digital vessels and hyperemia
in the recovery phase [1]. It is not a very rare symptom
and its prevalence ranges from 3% to 5% [2]. RP can be
classified as Raynaud’s syndrome, when there is an asso-
ciated disease. Meanwhile, it can be referred to as Ray-
naud’s disease, when there is no clear aetiology [3]. RP
may be mediated and aggravated by three mechanisms:
(i) neurogenic disorders, (ii) inadequate interaction be-
tween blood and vessel walls, (iii) changes in immune* Correspondence: sangwonlee@yuhs.ac
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stated.regulation [3]. Among immune-mediated conditions af-
fecting the development of RP, systemic sclerosis (SSc) is
the most common, representing 85% of such cases [4].
SSc is a systemic autoimmune disease characterized by
vasculopathy and fibrosis of both the skin and internal
organs, with pulmonary arterial hypertension, interstitial
lung disease and gastrointestinal manifestations [5-8].
The typical pathological features of SSc are mostly pro-
gressive and irreversible, so it could often reduce one’s
quality of life and be fatal enough to shorten life expect-
ancy [9]. Thus, there is a need to slow down the pro-
gression of SSc, but the efficacies of several therapeutic
modalities, that have been assessed in clinical trials, have
not yet been fully validated. Considering the intractable
and serious systemic complications of SSc and the lack
of established predictive values for their development,is is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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would provide better opportunity to monitor its devel-
opment or progression. From a clinical point of view, RP
might be a valuable clue prior to the initiation of SSc for
the following reasons: (i) SSc is the most common
immune-mediated aetiology of RP, (ii) RP is a clinical
feature frequently observed in the early phase of SSc,
(iii) RP can often precede skin and visceral fibrosis in
SSc [4]. Nevertheless, the 1980 American College of
Rheumatology (ACR) classification criteria for SSc did
not include an item for RP [10].
More recently, the ACR and the European League
Against Rheumatism (EULAR) recommended the new
classification criteria for SSc [11]. Their new classifica-
tion criteria have a notable feature in that they include
new variables on clinical features in the early phases of
the disease such as RP, puffy finger, and telangiectasia,
and the test results of capillary microscopy and autoanti-
body tests [11]. With these changes, they raised the sen-
sitivity of classification by up to approximately 15 to
20%, compared to the previous classification criteria.
Thus, in this study, we investigated how many pa-
tients, who presented with RP and who had not been
classified as SSc, would be reclassified as SSc, if the 2013
ACR/EULAR classification criteria were used. We also
analyzed the predictive values of the reclassification as
SSc in those patients.
Methods
Patients
We consecutively enrolled 64 patients (58 women, 6
men) with RP who had not been classified as SSc by the
1980 ACR classification criteria, and who had been re-
ferred to the Division of Rheumatology, Yonsei Univer-
sity Severance Hospital, from November 2013 to May
2014 for evaluating the underlying causes of their RP.
We applied the 2013 ACR/EULAR classification criteria
to 64 patients with RP, and we further assessed several
classification criteria for various rheumatic diseases that
can cause RP or RP-like symptoms. We also consecu-
tively enrolled 60 patients (52 women, 8 men) who had
been classified as SSc at the same institution, and who
visited our division during the same time period. We ap-
plied the 2013 ACR/EULAR classification criteria for
SSc to both RP and SSc patients as classified by the
1980 ACR classification criteria. Patients with a total
score of ≥9 were reclassified as SSc [11]. After the re-
classification, we compared variables between those who
were newly classified as SSc and those who were not.
We also assessed the predictive value of the reclassifica-
tion for variables that significantly differed between the
groups. In addition, we compared variables between pa-
tients who were newly classified as SSc versus those who
had been classified as SSc by the previous criteria. Thisstudy was approved by the Institutional Review Board of
Severance Hospital. Informed consent was obtained
from all patients.
Data collection
We made a short clinical research form consisting of all
variables that are described in the 2013 ACR/EULAR
classification criteria for SSc, except anti-RNA polymer-
ase III antibody, because this test was not routinely
available at our institute. Two rheumatologists per-
formed physical examinations, collected blood samples
for autoantibodies related to SSc, and completed the
clinical research form with cross-sectional data as fol-
lows: epidemiological characteristics including age, sex
and duration of RP, clinical variables including proximal
scleroderma, puffy finger, sclerodactyly, digital tip ulcer,
fingertip pitting scar, telangiectasia, nailfold capillaries
findings by nailfold capillaroscopy, pulmonary arterial
hypertension and interstitial lung disease during follow-
up. Pulmonary arterial hypertension was scored when it
had been confirmed by cardiac catheterisation, which
was performed in patients showing significantly elevated
right ventricular systolic pressure on baseline echocardi-
ography. Interstitial lung disease was defined when it
had been detected on a chest X-ray or high-resolution
computed tomography (HRCT). A chest X-ray was per-
formed in all patients, but HRCT was conducted in only
49 of 124 participants and only 17 of 64 patients with
RP who were suspected of interstitial lung disease based
on simple chest X-ray studies. There were no significant
differences in the rate of performing HRCT between pa-
tients reclassified as SSc versus those who were not re-
classified. We also assessed the presence of SSc-related
autoantibodies, including anti-centromere antibody or a
centromere pattern seen on antinuclear antibody test,
and anti-Scl-70 antibody in all patients. We counted
clinical symptoms and radiological or laboratory results
as positive items of the new classification criteria
through three conditions: (1) physical examination at
the time the patient provided informed consent, (2) re-
view of systems and medical history taking, and (3) re-
view of electronic medical records.
Statistical analysis
All statistical analyses were conducted using the SPSS soft-
ware (ver. 20.0 for Window; IBM Corp., Armonk, NY,
USA). Levels of continuous variables were expressed as
means ± standard deviations. Continuous variables between
the two groups were compared using Mann–Whitney U
tests, and non-continuous variables of age, sex and the
presence of autoimmune disease, clinical manifestations
and autoantibodies were assessed using a chi-square test.
The odds ratio (OR) was assessed using a multivariate lo-
gistic regression test among variables with P values <0.05 in
Table 1 Patients’ characteristics, clinical manifestations
and laboratory results in patients with Raynaud’s
phenomenon
Variables Patients with Raynaud’s
phenomenon (N = 64)
Characteristics
Age (years old) 50.9 ± 14.4
Sex, female (N (%)) 58 (90.6)
Raynaud’s phenomenon duration (years) 5.3 ± 7.7
Newly classified to systemic sclerosis
by the 2013 ACR/EULAR classification
criteria (N (%))
17 (26.5)
Autoimmune disease accompanied (N (%)) 33 (51.6)
Sjögren syndrome 15 (23.4)
Systemic lupus erythematosus 8 (12.5)
Mixed connective tissue disease 5 (7.8)
Rheumatoid arthritis 3 (4.7)
Inflammatory myopathy 2 (3.1)
Clinical manifestations (N (%))
Scleroderma (proximal) 0 (0)
Puffy finger 34 (53.1)
Sclerodactyly 7 (10.9)
Digital tip ulcer 2 (3.1)
Fingertip pitting scar 0 (0)
Telangiectasia 7 (10.9)
Abnormal nailfold capillaries 46 (71.8)
Pulmonary arterial hypertension 1 (1.6)
Interstitial lung disease 5 (7.8)
Autoantibodies (N (%))
Antinuclear antibody (centromere) 19 (29.7)
Anti-centromere antibody 22 (34.4)
Anti-Scl-70 antibody 2 (3.1)
Values are expressed as N (%) or mean ± standard deviation. ACR, American
College of Rheumatology; EULAR, The European League Against Rheumatism.
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P values <0.05 were considered to indicate statistical
significance. We also applied Bonferroni correction to var-
iables with statistical significance by making uncorrected
P values doubled as Bonferroni-adjusted P values, since
only two comparative analyses among three subgroups
were needed in this study.
Results
Baseline characteristics of patients who had RP, but who
had not previously been classified as SSc
Baseline characteristics are described in Table 1. The
mean age was 50.9 years old and 58 patients were fe-
male. The mean RP duration was 5.3 years. Seventeen of
64 patients (26.5%), who presented with RP, but did not
fulfill the 1980 ACR classification criteria, were newly
classified as SSc by the 2013 ACR/EULAR classification
criteria. Also, 33 of 64 patients (51.6%) had autoimmune
diseases other than SSc, and satisfied the classification
criteria for those autoimmune diseases [12-16]: 15 had
Sjögren syndrome, 8 had systemic lupus erythematosus,
5 had mixed connective tissue disease, 3 had rheumatoid
arthritis, and 2 had inflammatory myopathy. Puffy finger
(53.1%) was the most frequently observed clinical feature
followed by sclerodactyly (10.9%) and telangiectasia
(10.9%). Moreover, 46 patients (71.8%) showed abnormal
nailfold capillaries, 5 had interstitial lung disease, and 1
had pulmonary arterial hypertension. Antinuclear anti-
body was detected in 36 of 64 patients with RP (56.3%).
Furthermore, a centromere pattern on immunofluores-
cence was seen in 19 patients (29.7%). Anti-centromere
and anti-Scl-70 antibodies were found in 22 (34.4%) and
2 (3.1%) patients, respectively.
Comparison of variables between patients who were
versus those who were not reclassified as SSc according
to the new classification criteria
We divided patients, who presented with RP and who
had not been classified as SSc by the previous classifica-
tion criteria, into two groups according to the 2013
ACR/EULAR classification criteria (17 patients were re-
classified as SSc and 47 were not), and compared their
variables. There were no significant differences in age,
sex, RP duration or the presence of accompanying auto-
immune diseases between the two groups. The mean
2013 ACR/EULAR classification criteria score in patients
reclassified as SSc was 10.5, while that in patients not re-
classified was 6.1 (Table 2). In particular, the reclassified
patients showed increased frequencies of sclerodactyly,
digital tip ulcer, telangiectasia, abnormal nailfold capil-
laries and the presence of anti-centromere antibody
(Table 2). When we applied Bonferroni correction to the
statistical analysis, variables with statistical significance
still showed Bonferroni-adjusted P value <0.05.Comparison of variables between patients who were
newly classified as SSc and those who had been
previously classified as SSc
When we applied the 2013 ACR/EULAR classification
criteria to patients who had been classified as SSc by the
1980 ACR classification criteria, we found that all of the
patients with SSc also met the new classification criteria.
We compared variables between the newly classified and
previously classified patients; the results are summarised
in Table 3. There were no significant differences in age
or sex between the two groups. The previously classified
patients exhibited higher 2013 ACR/EULAR classifica-
tion criteria scores than the newly classified ones (19.1
vs. 10.5, P <0.001). Nineteen (31.7%) of the previously
classified patients presented with fingertip pitting scar,
Table 2 Comparison of variables between patients who were or were not reclassified as systemic sclerosis according to
the 2013 ACR/EULAR classification criteria for systemic sclerosis
Variables Patients reclassified as
systemic sclerosis (N = 17)
Patients not reclassified
as systemic sclerosis (N = 47)
P value P value*
Characteristics
Age (years old) 48.9 ± 12.4 51.7 ± 15.1 NS
Sex, female (N (%)) 17 (100) 41 (87.2) NS
Raynaud’s phenomenon duration (years) 3.4 ± 2.4 6.1 ± 9.0 NS
The 2013 ACR/EULAR classification criteria score 10.5 ± 1.8 6.1 ± 1.7 <0.001 <0.001
Autoimmune disease accompanied (N (%)) 10 (58.8) 23 (48.9) NS
Sjögren syndrome 4 (23.5) 11 (223.4) NS
Systemic lupus erythematosus 4 (23.5) 4 (8.5) NS
Mixed connective tissue disease 2 (11.8) 3 (6.4) NS
Rheumatoid arthritis 2 (11.8) 1 (2.1) NS
Inflammatory myopathy 1 (5.9) 1 (2.1) NS
Clinical manifestations (N (%))
Scleroderma (proximal) 0 (0) 0 (0) NS
Puffy finger 12 (70.6) 22 (46.8) NS
Sclerodactyly 6 (35.2) 1 (2.1) <0.001 <0.001
Digital tip ulcer 2 (11.8) 0 (0) 0.017 0.034
Fingertip pitting scar 0 (0) 0 (0) NS
Telangiectasia 5 (29.4) 2 (4.3) 0.004 0.008
Abnormal nailfold capillaries 17 (100) 29 (61.7) 0.003 0.006
Pulmonary arterial hypertension 0 (0) 1 (2.1) NS
Interstitial lung disease* 2 (11.8) 3 (6.4) NS
Autoantibodies (N (%))
Antinuclear antibody (centromere) 9 (52.9) 16 (34.0) NS
Anti-centromere antibody 11 (64.7) 11 (23.4) 0.002 0.004
Anti-Scl-70 antibody 0 (0) 2 (4.3) NS
Values are expressed as N (%) or mean ± standard deviation. P value* = Bonferroni-adjusted P value among variables with statistical significance. ACR, American
College of Rheumatology; EULAR, The European League Against Rheumatism; NS, not significant.
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sclerodactyly and interstitial lung disease were more fre-
quent in the previously classified patients, while telangi-
ectasia was more frequent in the newly classified patients.
The detection rates of antinuclear antibody (centromere)
and anti-centromere antibody in the newly classified pa-
tients were higher than those in previously classified pa-
tients. However, anti-Scl-70 antibody was only detected in
the previously classified patients. When we applied
Bonferroni correction to the statistical analysis, variables
with statistical significance still showed Bonferroni-
adjusted P value <0.05.
The predictive value of reclassification strategy
In multivariate logistic regression analyses of variables
with significant differences between patients who were
or were not newly classified (Table 2), the variables withindependent predictive value were sclerodactyly (OR
60.025, P = 0.002), telangiectasia (OR 13.353, P = 0.030)
and the presence of anti-centromere antibody (OR
11.168, P = 0.005) (Table 4).
Discussion
We enrolled patients who presented with RP, but who
were not classified as SSc according to the previous classi-
fication criteria to assess the effectiveness of the new clas-
sification criteria for SSc and investigate potential clues to
RP. For early classification of SSc, RP has several advan-
tages in that RP and SSc have common immune-mediated
aetiologies; RP is the sole self-reported symptom that oc-
curs in the early phase of the disease, and it can precede
typical fibrosis. In the present study, 17 of 64 patients
(26.5%), who presented with RP, but did not fulfill the
1980 ACR classification criteria, were newly classified as
Table 3 Comparison of variables between patients who were newly classified as systemic sclerosis according to the
2013 ACR/EULAR classification criteria for systemic sclerosis and those who had been previously classified
Variables Patients newly classified
as systemic sclerosis (N = 17)
Patients previously classified
as systemic sclerosis (N = 60)
P value P value*
Characteristics
Age (years old) 48.9 ± 12.4 51.1 ± 13.1 NS
Sex, female (N (%)) 17 (100) 52 (86.7) NS
The 2013 ACR/EULAR classification criteria score 10.5 ± 1.8 19.1 ± 5.1 <0.001 <0.001
Clinical manifestations (N (%))
Scleroderma (proximal) 0 (0) 40 (66.7) <0.001 <0.001
Puffy finger 12 (70.6) 27 (45.0) NS
Sclerodactyly 6 (35.2) 55 (91.7) <0.001 <0.001
Digital tip ulcer 2 (11.8) 20 (33.3) NS
Fingertip pitting scar 0 (0) 19 (31.7) 0.008 0.016
Telangiectasia 5 (29.4) 5 (8.3) 0.022 0.044
Abnormal nailfold capillaries 17 (100) 56 (93.3) NS
Pulmonary arterial hypertension 0 (0) 3 (5.0) NS
Interstitial lung disease* 2 (11.8) 29 (48.3) 0.007 0.014
Autoantibodies (N (%))
Antinuclear antibody (centromere) 9 (52.9) 12 (20.0) 0.007 0.014
Anti-centromere antibody 11 (64.7) 13 (21.6) 0.001 0.002
Anti-Scl-70 antibody 0 (0) 29 (48.3) <0.001 <0.001
Values are expressed as N (%) or mean ± standard deviation. P value* = Bonferroni-adjusted P value among variables with statistical significance. ACR, American
College of Rheumatology; EULAR, The European League Against Rheumatism; NS, not significant.
Table 4 The predictive values for the reclassification of
systemic sclerosis in patients who showed Raynaud’s
phenomenon and who had not been classified as
systemic sclerosis
Variables OR 95% confidence interval
Sclerodactyly 60.025 4.311 - 835.753
Digital tip ulcer NS NS
Telangiectasia 13.353 1.292 - 137.961
Abnormal nailfold capillaries NS NS
Anti-centromere 11.168 2.076 - 60.073
OR, odds ratio; NS, not significant.
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was used. Although RP is a clinical feature and sign of SSc
and it can occur prior to fibrosis, the previous classification
criteria missed the potential of SSc in a significant number
of patients apparently without SSc who did present with
RP. Thus, we anticipate a better opportunity to categorise
and classify SSc in patients with RP using the 2013 ACR/
EULAR classification criteria and applying it earlier.
Recently, several observational studies have used im-
munosuppressive agents, such as mycophenolate mofetil
and rituximab, to delay or modify the disease course of
SSc, but the therapeutic efficacies of these agents have
not yet been fully validated [17-19]. However, consider-
ing the intractable and serious systemic complications of
SSc, including pulmonary arterial hypertension and
interstitial lung disease and the lack of proven predictive
values for their development or exacerbation, we antici-
pate a ‘window of opportunity’ to classify SSc earlier
[20]. Thus, we expect that the new classification criteria
for SSc including RP could provide a chance to regularly
monitor and follow up on major complications and not
miss the appropriate time to initiate therapeutic trials
for each systemic complication of SSc.
We found that patients, who were newly classified as
SSc, had sclerodactyly, digital pitting scar, tip ulcer, telangi-
ectasia, abnormal nailfold capillaries and anti-centromereantibody more frequently than those who were not reclas-
sified. Furthermore, sclerodactyly, telangiectasia and the
presence of anti-centromere antibody had independent
predictive value for the reclassification of SSc in patients
with RP; all of these variables are clinical and laboratory
features that are usually observed in the early phase of SSc
[1,11]. Moreover, they can be used to better monitor the
more serious systemic complications of SSc. Thus, when
patients visit the clinic, presenting with RP, we suggest that
physicians should apply the new classification criteria for
SSc, especially in patients who present with sclerodactyly
or telangiectasia or who have anti-centromere antibody.
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the newly and previously classified patients, although
sclerodactyly did not differ significantly between the two
groups, telangiectasia and anti-centromere were signifi-
cantly more frequent in the newly classified patients.
Our results also verify the attainment of one of the goals
of establishing the new classification criteria, namely, to
overcome the low sensitivity of the previous system for
detecting early-phase and limited types of SSc [11].
The strength of this study is that we first investigated
the rate of the reclassification as SSc in patients who pre-
sented with RP, but did not fulfill the previous classifica-
tion criteria. Furthermore, we obtained the independent
predictive value for reclassifying patients with RP as SSc.
Our study also had several limitations. First, it was s
cross-sectional study. Second, the severities of RP and
other clinical manifestations were relatively high because
our hospital is a tertiary institution. Third, we did not
perform anti-RNA polymerase III test, which might have
affected the rate of reclassification [11].
Conclusions
Overall, 26.5% of the patients, who presented with RP,
but who did not fulfill the 1980 ACR classification cri-
teria, were newly classified as SSc according to the 2013
ACR/EULAR classification criteria. Sclerodactyly, tel-
angiectasia, and the presence of anti-centromere anti-
body had independent predictive value for reclassifying
patients with RP as SSc.
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